Vedolizumab-First in UC Linked to More Steroid-Free Stability

This Swedish nationwide cohort informs first-line advanced therapy selection in biologic-naive ulcerative colitis by comparing a vedolizumab-first versus TNF antagonist-first strategy over 5 years.

📅 Journal publication: Sep 1, 2026 · Last updated: Oct 6, 2026

vedolizumabinfliximabadalimumabTNF antagonistsanti-integrinulcerative colitisinflammatory bowel diseasebiologicstreatment sequencingcohort studySWIBREGcorticosteroid-free remission Gastroenterology / Hepatology

Background Information

Vedolizumab delivers better long-term stability in UC than TNF antagonists.

Choosing the optimal first-line advanced therapy for ulcerative colitis (UC) can impact long-term outcomes and disease stability. Vedolizumab initiators had a higher proportion of corticosteroid-free stability (67% vs 60-67% of quarters) compared to infliximab or adalimumab, despite similar hospitalization rates. Vedolizumab-first strategy results in better corticosteroid-free disease stability, which may aid in treatment decisions for biologic-naive UC patients. Vedolizumab leads to greater corticosteroid-free disease stability than TNF antagonists in UC.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Singh S, Söderling J, Forss A, Rask-Andersen M, Halfvarson J, Everhov ÅH, Ludvigsson JF, Olén O, SWIBREG study group

Citation: Singh S, Söderling J, Forss A, et al. Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis. JAMA network open. 2026;9(9):e2636165. doi:10.1001/jamanetworkopen.2026.36165

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →